Side-by-side comparison

ABT vs PFE — Side-by-side comparison

PFE screens cheaper on EV/FCF, ABT has the higher ROIC, PFE has grown revenue faster over five years, and ABT has the cleaner balance sheet by net debt / EBITDA.

ABT

Abbott Labs

Price

$87.41

Market cap

$230.7B

Day %

N/A

PFE

Pfizer Inc.

Price

$25.90

Market cap

$135.4B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


ABT Target	Abbott Labs	$230.7B	23.5x	31.8x	10.0%	5.1%	16.7%	N/A	0.5x	N/A
PFE	Pfizer Inc.	$135.4B	19.0x	14.8x	9.0%	8.5%	14.5%	N/A	N/A	N/A

ABT implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

31.8x

FCF yield

3.2%

5Y rev CAGR

5.1%

PFE implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

14.8x

FCF yield

6.7%

5Y rev CAGR

8.5%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for ABT.

Grade C

/ 100

Quality Radar0 – 20 per axis

Quality Scorecard

Build-time composite score for PFE.

Grade D

/ 100

Quality Radar0 – 20 per axis